User Reviews for Abstral
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Breakthrough Pain | 2 reviews | 6 medications |
Reviews may be moderated or edited before publication to correct grammar and spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest in the medication will not be published. As reviews and ratings are subjective and self-reported, this information should not be used as the basis for any statistical analysis or scientific studies.
For Breakthrough Pain: “I was enrolled in a clinical trial for abstral 7 months ago. This worked well for me so my pain doc started giving it to me. Now my doc is being told I am not allowed to use it because I don't have a diagnosis of cancer. I have lupus, fibromyalgia and rheumatoid arthritis which are quite debilitating most of the time. If I am not having a lupus flare up, I'm having a fibromyalgia flare up or a RA flare up, so I never know when I'm going to have a hard day or a good day. I don't wish for cancer but I do wish the pharmaceutical companies would realize that cancer patients area to the only ones in chronic breakthrough pain. Abstral works well and works in five to eight minutes. ”
This information is NOT intended to endorse any particular medication. While these reviews might be helpful, they are not a substitute for the expertise, knowledge and judgement of healthcare practitioners.
More about Abstral (fentanyl)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Imprints, Shape & Color Data
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: narcotic analgesics
- FDA Alerts (12)
- FDA Approval History
Consumer resources
- Other brands
- Duragesic, Fentanyl Transdermal System, Sublimaze, Fentora, ... +5 more
For Breakthrough Pain: “This drug merely gives a feel good factor and feeling of energy to do thinks that never happen. It is highly addictive . The withdrawal symptoms are awful and the NHS do not know how to treat patients withdrawing from this. It should be used at end of life or for in patients only.”